Formulary
Laronidase: Indications, Dosing, Side Effects and Interactions
Laronidase is an enzyme produced by recombinant DNA technology licensed for long-term replacement therapy in the treatment of non-neurological manifestations...
MedNext Academy | 3 min read
Laronidase: Indications, Dosing, Side Effects and Interactions
Laronidase is an enzyme produced by recombinant DNA technology licensed for long-term replacement therapy in the treatment of non-neurological manifestations...
Drug action
Laronidase is an enzyme produced by recombinant DNA technology licensed for long-term replacement therapy in the treatment of non-neurological manifestations of mucopolysaccharidosis I, a lysosomal storage disorder caused by deficiency of alpha-L-iduronidase.
Indications and dose
**Non-neurological manifestations of mucopolysaccharidosis I (specialist use only)**
- **Adult** (By Intravenous Infusion): 100 units/kg once weekly.
**Non-neurological manifestations of mucopolysaccharidosis I (specialist use only) for laronidase**
- **Child** (By intravenous infusion): 100 units/kg once weekly.
Cautions
Infusion-related reactions can occur
Side effects
Common or very common Abdominal pain; alopecia; anaphylactic reaction; angioedema; chills; cough; diarrhoea; dizziness; dyspnoea; fatigue; fever; flushing; headache; hypotension; influenza like illness; joint disorders; nausea; pain; pallor; paraesthesia; peripheral coldness; respiratory disorders; restlessness; skin reactions; sweat changes; tachycardia; temperature sensation altered; vomiting Frequency not known Cyanosis; hypoxia; oedema Side-effects, further information Infusion-related reactions often occur, they can be managed by slowing the infusion rate or interrupting the infusion, and can be minimised by pre-treatment with an antihistamine and an antipyretic. Recurrent infusion-related reactions may require pre-treatment with a corticosteroid-consult product literature for details.
Interactions
**Other interactions (1):**
- Aldurazyme should not be administered simultaneously with chloroquine or procaine due to a potential risk of interference with the intracellular uptake of laronidase.
Pregnancy
Manufacturer advises avoid unless essential-no information available.
Breast feeding
Manufacturer advises avoid-no information available.
Medicinal forms
Clinical governance
**Author:** MedNext Clinical Team. **Clinical reviewer:** Dr Shameer Deen, MBBS, MS, MRCS. **Sources:** BNF, Indian Pharmacopoeia, CIMS India. **Correction:** Report errors at support@mednext.academy.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
FormularyBrowse all drugs
Search 1,850+ drug profiles.
Study Laronidase in the MedNext app
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary

